PsyBio Therapeutics Retains KCSA Strategic Communications for Investor Relations Services Apr 9, 2021
PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin Mar 23, 2021
PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Global Contract… Mar 2, 2021
PsyBio Therapeutics Comes To Market With Compelling Psychedelic Compound Synthesis Technology Feb 25, 2021
